- 11 hrs ago 7 Awesome And Easy Ways Of Treating Problems Associated With Dry Skin In Winters
- 12 hrs ago Amazon Great Indian Sale 2021: From Smart TV to AC, Get Upto 50% Off On Cool Home Appliances
- 15 hrs ago Chhorii Promotions: Nushrratt Bharuccha Looks Stunning In Her Indigo-Blue And Ivory Outfits
- 16 hrs ago Covishield's Effectiveness In Fully Vaccinated Individuals 63% During 2nd Wave, Study
- Movies Akhanda Twitter Review: 10 Tweets You Should Read Before Watching The Nandamuri Balakrishna Starrer!
- Technology List Of Smartphones To Expected To Launch In December 2021
- News Manjinder Singh Sirsa quits as DSGMC president, joins BJP
- Sports Abu Dhabi T10: Hasaranga chokes Bangla Tigers with a fifer after Kohler-Cadmore's sparkling 96
- Education MPSC Subordinate Services Prelim Result 2020 Out, Check MPSC Subordinate Services Pre STI ASO Results Here
- Automobiles Tata Motors Has Registered Total Sales Of 62,192 Units In November 2021
- Finance Vodafone Idea Shares Continue To Gain Post Prepaid Plan Tariff Hike; Spikes 20% Intra-day
- Travel Budget Friendly Winter Places To Visit Around Shillong
The European Medicines Agency, the EU's regulator for medicinal products, on Thursday approved the BioNTech-Pfizer vaccine, also known as Comirnaty, for children aged 5-11. It's the first vaccine approved for children under 12 in the 27-member EU.The vaccine has already been approved in the EU for use in people between the ages of 12 and 17 years since May and for adults since December 2020.
EMA said the vaccine should be given to children in two doses of 10 micrograms three weeks apart as an injection in the upper arm. Adult doses contain 30 micrograms. "The benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19," EMA said.
Vaccinating children seen as key
The companies said a clinical trial of children aged 5 to 11 showed their vaccine to be 90.7% effective against the coronavirus. However, the studies have not been large enough to determine whether the vaccine could produce rare side effects such as chest and heart inflammation that have been seen in mostly male older teenagers and young adults after the second dose.
The approval for younger children comes as Europe battles another massive surge of COVID-19 cases. Authorities in Austria, which is seeing a very high rate of infections, did not wait for EMA approval and have already begun vaccinating the 5 to 11 age group.
In Germany and the Netherlands, children now account for the majority of cases, and experts say that vaccinating them could be vital to bringing the fourth wave of the pandemic under control. COVID-19 death in Germany reached 100,000 on Thursday.
What happens now?
EMA approval now has to be rubber-stamped by the EU's executive branch, the European Commission, before the vaccination can be rolled out for the 5-11 age group in EU member states. It typically follows EMA guidelines.
German Health Minister Jens Spahn said earlier this week that shipping of vaccines for younger children in the EU would begin on December 20. Germany's standing vaccination committee (STIKO) is due to issue its recommendation on vaccinating children aged 5-11 before the end of the year.
tj/msh (Reuters, AFP)